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REVIEWNeutrophils as Components of Mucosal Homeostasis
Caroline H. T. Hall,1,2 Eric L. Campbell,2,3,4 and Sean P. Colgan2,3
1Department of Pediatrics, 2Department of Medicine, 3Mucosal Inﬂammation Program, University of Colorado School of
Medicine, Aurora, Colorado; 4Centre for Experimental Medicine, Queen’s University Belfast, Northern Ireland, United KingdomSUMMARY
There is recent appreciation that neutrophils contribute
signiﬁcantly more to innate immunity than just their func-
tion in battling infection. It is now clear that neutrophils can
inﬂuence tissue metabolism, the composition of the micro-
biome, and communication between cell types through the
release of microparticles. This article highlights the role of
neutrophils in both homeostasis and pathology in mucosal
surfaces.
Inﬂammatory responses in the intestinal mucosa
inevitably result in the recruitment of neutrophils
(polymorphonuclear leukocytes [PMNs]). Epithelial cells
that line the mucosa play an integral role in the recruit-
ment, maintenance, and clearance of PMNs at sites of
inﬂammation. The consequences of such PMN–epithelial
interactions often determine tissue responses and, ulti-
mately, organ function. For this reason, there is signiﬁcant
interest in understanding how PMNs function in the mu-
cosa during inﬂammation. Recent studies have shown that
PMNs play a more signiﬁcant role in molding of the im-
mune response than previously thought. Here, we review
the recent literature regarding the contribution of PMNs to
the development and resolution of inﬂammation, with an
emphasis on the role of the tissue microenvironment and
pathways for promoting epithelial restitution. These
studies highlight the complex nature of inﬂammatory
pathways and provide important insight into the
difﬁculties of treating mucosal inﬂammation. (Cell Mol
Gastroenterol Hepatol 2017;4:329–337; http://dx.doi.org/
10.1016/j.jcmgh.2017.07.001)
Keywords: Epithelium; Microbiota; Inﬂammation; Hypoxia-
Inducible Factor; Metabolism.
primary function of the intestinal mucosa is to
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http://dx.doi.org/10.1016/j.jcmgh.2017.07.001Aprovide a selective barrier to the outside. The
potential for infection by pathogenic organisms and the
necessity to communicate with commensal microorganisms
exist on the same surfaces. In this regard, tissue healing
after injury occurs in conjunction with the constant ﬂux of
new antigenic material and requires that the mucosal
immune system appropriately dampen inﬂammatory and
immunologic reactions to harmless ingested antigens. The
overlying epithelium plays an important role in coordinating
both inﬂammation and resolution. The epithelium lies
juxtaposed to the mucosal immune system and lines theentire gastrointestinal (GI) tract. Covering a surface area of
approximately 300 m2, the human adult intestinal epithe-
lium consists of a monolayer of cells with intercellular tight
junctions, a complex 3-dimensional structure, and a thick
mucous gel layer that provides a dynamic and regulated
barrier to the ﬂux of the luminal contents to the lamina
propria.1,2 It is widely understood that the GI tract exists in
a state of low-grade inﬂammation. Such a state results from
the constant processing of luminal antigenic material and
the priming of the mucosal immune system for rapid and
effective responses to antigens or microbes that may
penetrate the barrier.3
The presence of polymorphonuclear leukocytes (PMNs)
at sites of tissue injury and infection has long been
recognized as a hallmark of mucosal inﬂammation.4 It
increasingly has become appreciated that the presence of
PMNs at sites of injury do not necessarily prove causation to
tissue damage, and, in fact, a number of studies now suggest
that PMNs provide important cues that promote inﬂamma-
tory resolution and a return to mucosal homeostasis. In this
review, we discuss recent literature regarding the role of
microbiota in the recruitment of PMNs to the mucosal
surface, the critical role of PMNs in oxygen metabolism, and
implicating PMNs in promoting homeostasis in the mucosa.
Microbiota Promote PMN Recruitment
into the Mucosa
The mammalian GI tract plays host to trillions of bacte-
ria, viruses, and fungi, collectively termed the microbiota. A
ﬁnely balanced mutualism exists within the intestinal mu-
cosa, in that microbes are essential for intestinal health but
also can be involved in inﬂammation and pathologic dam-
age.5 Because PMNs provide the ﬁrst line of defense to
infection, PMNs frequently interact with the commensal
microbiome. In general, PMNs do not initiate inﬂammation
in these interactions with commensal microbes. In past
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signiﬁcantly impacts the development and activation of the
immune system, including PMNs.
Circulating neutrophils increase within days after birth
in human neonates. In a study of antibiotic treatment of
pregnant mice, neonatal pups born to these mice developed
a reduced number and altered composition of microbes as
compared with mice not treated with antibiotics.6 This mi-
crobial shift correlated with reduced numbers of
neutrophils, fewer Ly6Gþ cells in the bone marrow, and
decreased circulating granulocyte colony-stimulating factor.
This relative neutropenia was similar in germ-free mice.
Prior work had identiﬁed interleukin (IL)17 as a key regu-
lator of granulocyte colony-stimulating factor and gran-
ulocytosis.7,8 Indeed, IL17-producing cells were reduced in
these antibiotic-treated and germ-free mice. The IL17 pro-
duction was not dependent on the adaptive immune system
because RAG-deﬁcient mice had persistent IL17 production
and neutrophil recruitment. The neutropenia associated
with antibiotic therapy in these mice resulted in increased
susceptibility to sepsis, arguing for a protective role for
microbiota-stimulated PMN production and recruitment.
This neutropenia was reversed with reconstitution of
normal microbiome after antibiotic therapy.
Beyond bacterial load and composition, speciﬁc bacteria
have been shown to change PMN populations. Segmented
ﬁlamentous bacteria, for example, have been shown to induce
IL17- and CXCR2- (PMN receptor for IL8) dependent
recruitment of neutrophils9 (Figure 1). Segmented ﬁlamen-
tous bacteria are spore-forming, gram-positive, ﬁlamentous
bacteria ranging between 1 and 2 mm in diameter and as long
as 80 mm in length that colonize the intestine of mice at the
time of weaning.10 Unlike the IL17-dependent PMN recruit-
ment in the prior neonatal study, the IL17 production was
dependent on the adaptive immune system because PMNrecruitment was not appreciated in RAG-deﬁcient mice. In
neutrophil-depleted mice with ﬁlamentous bacterial coloni-
zation, bacterial expansion and IL17-producing cells were
increased, suggesting a negative feedback of neutrophils on
IL17 production. Other studies have had similar ﬁndings that
germ-free and antibiotic-treated mice have decreased
neutrophilic response to peritoneal inﬂammation.11
Recruitment in this experimental model was MyD88-
dependent. Another study identiﬁed that reconstitution of
PMN number in germ-free mice can be achieved by serum
transfer from mice with a conventional microbiome,
suggesting that a soluble factor (eg, IL17) is integral to PMN
recruitment.12 These studies contribute to the conﬂicting
data regardingwhether IL17 ismore pathogenic or protective
in the GI tract. These data speak to the importance of IL17 to
recruitment of PMNs necessary to ﬁght infections. Other
studies point to the pathogenic, proinﬂammatory role of this
cytokine, particularly IL17F, in the GI tract in diseases such as
inﬂammatory bowel disease (IBD).13
There are likely to be differences between various
mucosal surfaces with regard to the contribution of PMNs to
mucosal homeostasis. A comparison of the GI tract and the
lung for instance, suggests that the role of PMNs on tissue
function may be different. This particular aspect has been
shown convincingly in vivo. The depletion of circulating
PMNs using anti-Gr1 antibodies resulted in the exacerbation
of symptoms in a number of different murine colitis models,
strongly implicating PMNs as a central protective factor in
ongoing inﬂammation.14 By contrast, the depletion of PMNs
in acute lung injury models appears to have an
anti-inﬂammatory effect15 and severe disease has been
associated strongly with the presence of PMNs, driving the
argument that PMNsplay a key role in acute lung injury.16 It is
notable that this idea has been revisited to suggest that PMNs
can be eliminated effectively through mucociliary clearanceFigure 1. Selective com-
ponents of the micro-
biome inﬂuence PMN
recruitment to the mu-
cosa. The luminal micro-
biota, including
segmented ﬁlamentous
bacteria (SFB), provide
signals (eg, IL23 produc-
tion from multiple cell
types) that drive the accu-
mulation of Th17 cells in
the lamina propria. In turn,
Th17 cells secrete IL17,
which activates the release
of chemokines from
epithelial cells to promote
the accumulation of PMNs
at tissue sites.
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these results suggest differences in mechanisms of inﬂam-
matory resolution between various mucosal organs.
PMNs and Oxygen Metabolism in the
Regulation of Mucosal Function
Once at the tissue site, PMNs fundamentally can change
the metabolism of the mucosa. Some recent work, for
example, has indicated that PMNs signiﬁcantly change the
availability of oxygen to the surrounding tissue. Compared
with other mucosal tissues, the healthy intestine is relatively
hypoxic, existing at a PO2 of less than 40 mm Hg.
18,19 Studies
comparing functional responses in epithelial cells from
different tissues showed that intestinal epithelia uniquely
are resistant to low PO2 environments and that even very
low levels of O2 within the normal mucosa (so-called
physiologic hypoxia) may represent an adaptation to the
steep oxygen gradient that exists across the intestinal
lumen.20 These studies lead to the observation that epithe-
lial cells of the colon basally regulate the transcription factor
hypoxia-inducible factor (HIF),21 one of the global regula-
tors of gene expression in low O2 conditions.
22–24 Within the
colonic mucosa, it has been shown that the low O2 condi-
tions that enable microbial short-chain fatty acid production
(eg, acetate, propionate, and butyrate) also promote O2
consumption in a fashion that stabilizes HIF and maintains
basal expression of antimicrobial peptides25 and proteins
that sustain the mucosal barrier.26
Oxygen utilization via tissue metabolism is exacerbated
during inﬂammation. It recently was shown, for instance, that
during acute inﬂammatory disease, inﬁltrating PMNsmold the
tissue microenvironment in ways that signiﬁcantly promote
the stabilization of HIF.27 An unbiased proﬁling of epithelial
cells after PMN transmigration identiﬁed the regulation of a
cohort of HIF target genes. By using HIF reporter mice,
Gp91phox-/- mice (lack a respiratory burst), and PMN-depletion
strategies in acute colitis models, these studies showed that
transmigrating neutrophils deplete the surrounding tissue of
molecular oxygen in a reduced nicotinamide adenine dinu-
cleotidephosphate (NADPH)-oxidase–dependentmanner. As a
result of the profound oxygen depletion within the tissue
microenvironment, transmigrating PMNs transcriptionally
imprint a molecular signature onto the surrounding paren-
chyma (eg, epithelial cells) that signiﬁcantly reﬂects the
stabilization of HIF. This molecular signature promotes effec-
tive HIF-dependent tissue protection. At present, it is unclear
whether such imprinting occurs beyond the epithelium and
whether such changes are transient or reﬂectmore permanent
epigenetic modiﬁcations.
Gp91phox-/- mice developed highly accentuated colitis
relative to controls. They had exaggerated PMN inﬁltration,
diminished inﬂammatory hypoxia, and increased microbial
invasion.27 A clinical corollary to these ﬁndings is that
nearly half of patients who lack a functional NADPH oxidase
(ie, chronic granulomatous disease [CGD]) present with an
IBD-like syndrome.28,29 This NADPH oxidase complex is
responsible for the generation of reactive oxygen species
and is used by PMNs to kill invading pathogens andcommensal bacteria that have breached barriers and
interact with NADPH oxidase–expressing cells. Such clinical
observations suggest that CGD-associated IBD could
represent a failure to resolve acute intestinal insults.
Signiﬁcant localized oxygen consumption is associated
with acute inﬂammation30 (Figure 2). Numerous studies
have shown that such inﬂammatory hypoxia stabilizes the
transcription factor HIF in the surrounding tissue.31 Once
stabilized, HIF triggers the transcription of a cohort of genes
that enable intestinal epithelial cells to promote epithelial
restitution.20,32–34 Studies have shown that intestinal
epithelial cells subjected to low O2 regulate barrier-related
genes in a transcription-dependent manner.35 A number of
these target genes subsequently have been validated in
animal models of inﬂammation21,36–40 and in human
tissues.27,41–43 The functional proteins encoded by these HIF
target genes include those that localize primarily to the most
luminal aspect of polarized epithelia that contribute
fundamentally to effective barrier function. These target
genes include mucins,44 molecules that modify mucins
(eg, intestinal trefoil factor),20 xenobiotic clearance,32 anti-
microbial peptides,25 and nucleotide metabolism.34,35
The analysis of HIF as a component of the restitution
response during mucosal inﬂammation has guided the
development of pharmacologic molecules that function to
stabilize HIF and drive the expression of HIF target
genes.45,46 For the most part, the pharmacologic approach to
achieve HIF stabilization in normoxia has involved the
inhibition of HIF prolyl-hydroxylases (PHDs), originally
discovered as products of genes related to Caenorhabditis
elegans egl-9,47 and subsequently cloned in mammals as
PHD1, PHD2, and PHD3. These enzymes were shown to
hydroxylate HIF-a in vitro.47,48 Targeting the catalytic
domain of PHDs initially was achieved by a screen of
molecules that interfere with critical cofactors such as
2-oxoglutarate using mimetics that occupy the enzyme
(eg, dimethyloxalylglycine [DMOG]).49 Interestingly, the
addition of DMOG to a chemically induced colitis model
proved highly effective in promoting the resolution of
inﬂammation.36 A parallel study published at the same time
used a different PHD inhibitor (FG-4497) that was based on
a screen to identify erythropoietin inducers. Similar to
DMOG, FG-4497 blocks the active site of PHDs.49 In both
studies, HIF-stabilizer treatment was associated with
profound pro-resolving functions, particularly related to
mucosal barrier function.36,39 It is notable PHD inhibitors
are currently in development for renal anemia (erythro-
poietin induction)45 and that the use of local oral delivery of
an extended-release preparation to the inﬂamed mucosa
could represent a novel therapeutic apprch for IBD.
PMNs Monitor Innate Immune
Responses at the Surface of
the Mucosa
The rearrangements of tight junctions by transmigrating
PMNs remain insufﬁciently understood. Studies using
inhibitors of PMN proteases and PMNs from patients with
CGD suggests that the mechanism by which PMNs migrate
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production, respectively,50,51 but rather requires mechanical
impalement of the tight junction.
Studies using functionally inhibitory antibodies have
shown that b2 integrins are required for PMN migration
across epithelial surfaces52 (Figure 2). b2 integrins are het-
erodimeric glycoproteins that exist in 4 forms, each showing a
unique a-subunit (CD11a, b, c, or d) and an identical b-sub-
unit (CD18).53 PMN expression of CD11b/18, but not CD11a
or CD11c/18, is required for successful PMN transepithelial
migration.54 The role of adhesion-based receptors, b2 integ-
rins, are best shown in the genetic disorder leukocyte adhe-
sion deﬁciency. This is a rare disorder in which patients lack
normal expression of the b-subunit CD18 and, as a result,
have severe immunodeﬁcient symptoms.55 Similar to CGD,
leukocyte adhesion deﬁciency patients often manifest severe
mucosal disease.56,57 PMNs from leukocyte adhesion deﬁ-
ciency patients fail to migrate across intestinal epithelia,54
providing further evidence for the dependence of PMN
CD11/18 integrins on transmigration.
Transmigration through the paracellular space is
governed primarily by CD47, a membrane glycoprotein of
approximately 60 kilodaltons expressed in a polarizedFigure 2. O2 consumption by transmigrating PMNs stab
(A) Known steps of PMN transmigration. Recruitment signals lib
across the mucosa. Initial adhesion of PMNs is mediated by CD
of PMNs through the paracellular space is mediated by epitheli
PMN SIRP-a and junctional adhesion molecule-L (JAM-L), resp
CD11b/18-ICAM-1–dependent manner or cleared through ant
CD97. (B) PMN accumulation at such sites become activated
complex. As a result, the local tissue environment becomes dep
within the epithelium and surrounding parenchyma. The activatio
of inﬂammation within the mucosa, particularly related to barriefashion (basolateral) on epithelial cells. CD47 has homology
to the immunoglobulin supergene family.58 Further studies
have shown that CD47 functions in concert with signal-
regulatory protein-a (SIRPa), a cell-surface protein
containing 3 immunoglobulin superfamily domains and
intracellular immunoreceptor tyrosine-based inhibitory
motifs.59 CD47 is a ligand for Sirpa and studies have shown
that CD47 activity is proportional to the expression of Sirpa
and that Sirpa–CD47 interactions mediate cell–cell
interactions.60 Thus, it appears that CD47 is critically
important to regulated transepithelial migration (Figure 2).
Although the formation of crypt abscesses may serve as
histologic markers of ongoing inﬂammation, signiﬁcant ev-
idence suggests that PMN migration into the lumen is an
important part of innate immunity. For example, on reach-
ing the apical surface of the epithelium, PMNs bind to
intracellular adhesion molecule-1 (ICAM-1), which is
expressed in a polarized manner exclusively on the apical
epithelial surface.61 Sumagin et al62 recently showed that
binding of PMN CD11b/18 to epithelial ICAM-1 is associated
with decreased PMN apoptosis, thereby lengthening the life
of the PMNs within the lumen of the intestine. These
interactions of PMNs with ICAM-1 also were shown toilizes mucosal HIF and promotes epithelial restitution.
erated at inﬂammatory sites attract PMNs to migrate into and
11b/18 to a currently unknown basolateral ligand. Movement
al CD47 and coxsackie adenovirus receptor (CAR) binding to
ectively. Once at the apical surface, PMNs are retained in a
i-adhesive mechanisms involving epithelial CD55 and PMN
to consume large amounts of O2 via the NADPH oxidase
lete of molecular O2, which promotes the stabilization of HIF
n of multiple HIF target genes promotes the active resolution
r and antimicrobial function. TJ, tight junction.
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closure and epithelial proliferation. Furthermore, using co-
lon biopsy as a model of wounding, apical ICAM-1 was
found to be central to wound closure in the lumen of the
colon. Other studies have shown that apically localized
CD55 functions as an anti-adhesive molecule promoting the
clearance of epithelial-bound PMNs63,64 (Figure 2). Surface-
expressed CD55 has been shown to interact directly with
PMN CD97.65
At the luminal surface, PMNs serve as a prominent
reservoir for luminal adenosine precursors. Adenosine and
its analogs can ameliorate the course of a variety of inﬂam-
matory diseases.66 After transmigration, PMNs actively
release adenine nucleotides, particularly in the form of
adenosine triphosphate (ATP) or adenosine diphosphate.67
The phosphohydrolysis of ATP and adenosine mono-
phosphate by apically expressed apyrases (eg, CD39) and
ecto-5’-nucleotidase (CD73), respectively, represent the
major pathways for accumulation of extracellular adeno-
sine.34,35,68 Once liberated in the extracellular space,
adenosine either is recycled (eg, through dipyridamole-
sensitive carriers) or interacts with cell-surface Ado
receptors.69 Four subtypes of G-protein–coupled Ado
receptors exist, designated Adora1, Adora2a, Adora2b, or
Adora3, and are classiﬁed according to utilization of pertussis
toxin–sensitive (A1 and A3) or –insensitive (A2A and A2B)
pathways.69 Recent work speciﬁcally has implicated the
epithelial AA2BR in protection afforded by adenosine in
mucosal inﬂammation. For example, Aherne et al70 compared
Adora2b deletion in vascular endothelial cells (Adora2b[ﬂ/ﬂ]
VeCadCre[þ]) or intestinal epithelia (Adora2b[ﬂ/ﬂ]VillinCre
[þ]) and showed a selective role for epithelial Adora2b
signaling in attenuating colonic inﬂammation. Such protec-
tion was owing to Ado-dependent increases in adenosine
30,50-cyclic monophosphate that is accompanied by increased
actin polymerization and the cross-linking functions of
vasodilator-stimulated phosphoprotein. Given the transient
increase in epithelial permeability associated with PMN
transmigration, these studies indicate PMN-derived adeno-
sine signaling to the epithelial tight junction provides a signal
to close the door after leaving and, as such, serves an
important role in mucosal resolution (Figure 2).
Platelets are also a rich source of extracellular ATP.
Platelets release nucleotides at high concentrations upon
activation by collagen or adenosine diphosphate activation
of dense granule release.71 The co-migration of platelets and
PMNs has been observed in intestinal tissue derived from
human patients with IBD. Platelet–PMN clusters were found
to release large quantities of ATP, which were metabolized
to Ado to activate ﬂuid transport into the intestinal lumen.
This physiologic response has been suggested to serve as a
ﬂushing mechanism for mucosal-associated bacteria as part
of the innate immune response.72
PMN Microparticles as Conveyors of
Local Information
An area of signiﬁcant interest is the liberation of
microparticles from activated PMNs. Microparticles aresubcellular microvesicles that are shed from membranes
under a variety of conditions. Ranging in size from 100 nm
to 1 mmol/L, these membrane vesicles originally were
considered cellular debris but recently have become a topic
of considerable interest.73 Numerous studies now show that
microparticles carry lipid, protein, RNA, and DNA cargo as a
means of communication between cells, tissue, and even
organs.73 PMN-derived microparticles are increased signif-
icantly during inﬂammation and have shown signiﬁcant
promise as biomarkers, diagnostic tools, and as a contrib-
utor to the resolution of inﬂammation.74 For example, Dalli
et al75 compared the microparticle cargo in microparticles
from PMNs in suspension and adherent to endothelial cells.
These studies identiﬁed more than 400 proteins with nearly
half shared between the adherent and nonadherent groups.
Most notably, they showed that PMN-derived microparticles
were functional and had the capacity to generate leuko-
triene B4 and to elicit an oxidative burst. This same group
has shown that microparticle a-2-macroglobulin promotes
inﬂammatory resolution in murine models of sepsis.76
Conversely, other investigators have shown that PMN-
derived microparticles can promote inﬂammation through
delivery of myeloperoxidase77 and metalloproteinase-9.78
Other roles for PMN in Mucosal
Immunity
PMNs also play important roles in determining subse-
quent immune responses in the mucosa. PMNs are a newly
appreciated source of multiple chemokines and cytokines
because they have been shown to have the capacity to
express, produce, and secrete a broad range of both proin-
ﬂammatory and anti-inﬂammatory cytokines and chemo-
kines.79,80 PMNs also have the capacity to function as
suppressor cells. For instance, Bowers et al81 have shown
that when activated appropriately, PMNs can express high
levels of programmed death ligand-1, and through this ac-
tivity can suppress T-cell function. It also is possible that
PMNs, through actions on HIF stabilization (see earlier),
could be central to regulating the balance between regulator
T cells and Th17 differentiation. For instance, Dang et al82
showed that HIF-1 transcriptionally activates RORgt and
attenuates regulator T cell development by binding to
Foxp3. Other studies have shown that PMNs recruited to the
skin by bacterial infections migrate to the draining lymph
node where they augment lymphocyte proliferation.83 This
process was shown to be CD11b- and CXCR4-dependent and
occurs through direct PMN interactions with lymphatic
endothelial cells. Other investigators have shown that CD8
T-cell immune responses to mucosal viral infections are
initiated by PMN transport of virus to the bone marrow.84
Within these studies, it was suggested that PMNs could
contribute to antigen presentation and CD8 T-cell priming.
Conclusions
The trafﬁcking of PMNs to the mucosa represents an
important part of the innate immune response. Within the
mucosa, restitution of the epithelial barrier deﬁnes a critical
determinant of a productive inﬂammatory response. Recent
334 Hall et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 3studies investigating changes within the microenvironment
of acute inﬂammation have shown new important signaling
pathways initiated by activated PMNs. Studies in recent
years have identiﬁed components of the microbiome as
central players in productive and pathologic inﬂammatory
responses. Also notable is the shift in tissue oxygenation
toward hypoxia, and speciﬁcally HIF target pathways asso-
ciated with barrier restitution and altered cellular
bioenergetics that contribute fundamentally to productive
innate immunity. These adaptive metabolic pathways acti-
vated in response to PMN inﬁltration represent potentially
important therapeutic opportunities for the treatment of
mucosal inﬂammation.References
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